NDASUBCUTANEOUSPOWDER
Approved
Dec 2012
Lifecycle
Post-LOE
Competitive Pressure
35/100
Clinical Trials
29
Data completeness
6/8 — Strong
GATTEX KIT (teduglutide) by Takeda is glucagon-like peptide-2 (glp-2) agonists [moa]. Approved for glp-2 analog [epc]. First approved in 2012.
Drug data last refreshed Yesterday
Mechanism of Action
Glucagon-like Peptide-2 (GLP-2) Agonists
Pharmacologic Class:
GLP-2 Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (29)
A Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndrome
Started Mar 2026
12 enrolled
Short Bowel Syndrome (SBS)
A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome
Started Jun 2025
13 enrolled
Short Bowel Syndrome
A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (SBS) in Canada
Started Sep 2023
52 enrolled
Short Bowel Syndrome (SBS)
A Study With Teduglutide (Revestive®) in Adults With Short Bowl Syndrome
Started Jan 2022
65 enrolled
Short Bowel Syndrome
A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Aged 4 Months or Older
Started Jan 2022
3 enrolled
Short Bowel Syndrome
Worked on GATTEX KIT at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.